This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Jong Eun Yeon
Korea University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Noninvasive modalities exhibit limited diagnostic performance for evaluating the severity of nonalcoholic fatty liver disease (NAFLD). MicroRNAs (miRNAs) serve as useful biomarkers for diagnosing and monitoring disease progression and treatment response. Here, we evaluated whether serum exosomal miRNAs can be used to clinically predict the severity of NAFLD. Exosomal miRNAs were isolated from the sera of 41 NAFLD patients (diagnosed using biopsy) for array profiling. To compare differentially expressed miRNAs, the degree of severity was determined using inflammation, steatosis, ballooning, and NAFLD activity score (NAS). The correlation of miRNAs with clinical and biochemical parameters was analyzed. The correlation between miRNA and mRNA expression was analyzed by comparing our miRNA expression data with publicly available mRNA expression data. Twenty-five, eleven, thirteen, and fourteen miRNAs correlated with inflammation score, steatosis score, ballooning score, and NAS, respectively. Thirty-three significant correlations were observed between twenty-seven miRNAs and six clinical variables (age, ALP, AST, ALT, GGT, and NAS). In fibrosis, 52 and 30 interactions corresponding to high miRNA-low mRNA and low miRNA-high mRNA expression, respectively, were observed. We demonstrated that serum exosomal miRNAs can be used to evaluate NAFLD severity and also delineate potential targets for NAFLD treatment.
Keywords
MicroRNA, Exosome, NAFLD activity score, Liver fibrosis, Co-expression networks
Figure 1
Figure 2
Figure 3
Figure 4
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 05 Jan, 2021
No community comments so far
Editorial decision: Major revision
On 11 Mar, 2021
Reviewer #3 agreed
On 27 Feb, 2021
Review #3 received
Received 26 Jan, 2021
Review #20 received
Received 26 Jan, 2021
Review #22 received
Received 26 Jan, 2021
Review #21 received
Received 26 Jan, 2021
Review #23 received
Received 26 Jan, 2021
Review #18 received
Received 26 Jan, 2021
Review #17 received
Received 26 Jan, 2021
Review #1 received
Received 26 Jan, 2021
Review #19 received
Received 26 Jan, 2021
Review #2 received
Received 26 Jan, 2021
Reviewer #14 agreed
On 06 Jan, 2021
Reviewer #4 agreed
On 06 Jan, 2021
Reviewer #11 agreed
On 06 Jan, 2021
Reviewer #31 agreed
On 06 Jan, 2021
Reviewer #33 agreed
On 06 Jan, 2021
Reviewer #32 agreed
On 06 Jan, 2021
Reviewer #34 agreed
On 06 Jan, 2021
Reviewer #29 agreed
On 06 Jan, 2021
Reviewer #28 agreed
On 06 Jan, 2021
Reviewer #1 agreed
On 06 Jan, 2021
Reviewer #5 agreed
On 06 Jan, 2021
Reviewer #12 agreed
On 06 Jan, 2021
Reviewer #9 agreed
On 06 Jan, 2021
Reviewer #10 agreed
On 06 Jan, 2021
Reviewer #30 agreed
On 06 Jan, 2021
Reviewer #2 agreed
On 06 Jan, 2021
Reviewer #13 agreed
On 06 Jan, 2021
Reviewers invited
Invitations sent on 06 Jan, 2021
Editor assigned
On 06 Jan, 2021
Editor invited
On 31 Dec, 2020
Submission checks complete
On 31 Dec, 2020
First submitted
On 22 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Internal Medicine
Learn more about our company.
This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Jong Eun Yeon
Korea University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 05 Jan, 2021
No community comments so far
Editorial decision: Major revision
On 11 Mar, 2021
Reviewer #3 agreed
On 27 Feb, 2021
Review #3 received
Received 26 Jan, 2021
Review #20 received
Received 26 Jan, 2021
Review #22 received
Received 26 Jan, 2021
Review #21 received
Received 26 Jan, 2021
Review #23 received
Received 26 Jan, 2021
Review #18 received
Received 26 Jan, 2021
Review #17 received
Received 26 Jan, 2021
Review #1 received
Received 26 Jan, 2021
Review #19 received
Received 26 Jan, 2021
Review #2 received
Received 26 Jan, 2021
Reviewer #14 agreed
On 06 Jan, 2021
Reviewer #4 agreed
On 06 Jan, 2021
Reviewer #11 agreed
On 06 Jan, 2021
Reviewer #31 agreed
On 06 Jan, 2021
Reviewer #33 agreed
On 06 Jan, 2021
Reviewer #32 agreed
On 06 Jan, 2021
Reviewer #34 agreed
On 06 Jan, 2021
Reviewer #29 agreed
On 06 Jan, 2021
Reviewer #28 agreed
On 06 Jan, 2021
Reviewer #1 agreed
On 06 Jan, 2021
Reviewer #5 agreed
On 06 Jan, 2021
Reviewer #12 agreed
On 06 Jan, 2021
Reviewer #9 agreed
On 06 Jan, 2021
Reviewer #10 agreed
On 06 Jan, 2021
Reviewer #30 agreed
On 06 Jan, 2021
Reviewer #2 agreed
On 06 Jan, 2021
Reviewer #13 agreed
On 06 Jan, 2021
Reviewers invited
Invitations sent on 06 Jan, 2021
Editor assigned
On 06 Jan, 2021
Editor invited
On 31 Dec, 2020
Submission checks complete
On 31 Dec, 2020
First submitted
On 22 Dec, 2020
Subject Areas
Internal Medicine
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Noninvasive modalities exhibit limited diagnostic performance for evaluating the severity of nonalcoholic fatty liver disease (NAFLD). MicroRNAs (miRNAs) serve as useful biomarkers for diagnosing and monitoring disease progression and treatment response. Here, we evaluated whether serum exosomal miRNAs can be used to clinically predict the severity of NAFLD. Exosomal miRNAs were isolated from the sera of 41 NAFLD patients (diagnosed using biopsy) for array profiling. To compare differentially expressed miRNAs, the degree of severity was determined using inflammation, steatosis, ballooning, and NAFLD activity score (NAS). The correlation of miRNAs with clinical and biochemical parameters was analyzed. The correlation between miRNA and mRNA expression was analyzed by comparing our miRNA expression data with publicly available mRNA expression data. Twenty-five, eleven, thirteen, and fourteen miRNAs correlated with inflammation score, steatosis score, ballooning score, and NAS, respectively. Thirty-three significant correlations were observed between twenty-seven miRNAs and six clinical variables (age, ALP, AST, ALT, GGT, and NAS). In fibrosis, 52 and 30 interactions corresponding to high miRNA-low mRNA and low miRNA-high mRNA expression, respectively, were observed. We demonstrated that serum exosomal miRNAs can be used to evaluate NAFLD severity and also delineate potential targets for NAFLD treatment.
Figure 1
Figure 2
Figure 3
Figure 4
Loading...